MATHEMATICAL MODELING OF DRUG DOSAGE AND CONCENTRATION IN THE BLOODSTREAM
Notice: This is a sample project for study and reference. Submitting it as your own work violates most universities' academic integrity policies.
Abstract
About This Research Topic
Safe drug therapy hinges on maintaining plasma concentration within a therapeutic window—above the minimum effective concentration but below the toxic threshold. Pharmacokinetics quantifies how absorption, distribution, metabolism and excretion shape this time course. For orally administered drugs, concentration rises as drug is absorbed from gut to blood, then falls as elimination clears it. Understanding this rise-and-fall profile mathematically enables rational dosing design rather than trial-and-error prescribing. Browse mathematics and pharmacology project topics This article rewrites the original undergraduate project on compartmental modeling of drug dosage, preserving its analytical Bateman solution, RK4 validation, and renal impairment analysis while adding explanatory depth for Scholarnesthub readers.
Main Abstract
Effective pharmacotherapy requires plasma concentration to remain within a therapeutic window defined by minimum effective and maximum safe concentrations. This study develops a compartmental model of drug dosage and concentration dynamics as a one-compartment open model with first-order absorption and elimination, extended to a two-compartment model with peripheral tissue. The governing ODEs were solved analytically via the classical Bateman function and numerically via fourth-order Runge-Kutta (RK4) in Python. Numerical accuracy was confirmed: RK4 matched the analytical solution within 5.45×10⁻⁷ mg/L and an independent LSODA solver within 1.86×10⁻⁵ mg/L. Under baseline parameters for a moderately hydrophilic renally cleared drug (500 mg dose, F=0.85, ka=1.2 h⁻¹, V=38 L, CL=6.5 L/h), single-dose predictions were Cmax 8.09 mg/L at Tmax 1.9 h, AUC 65.38 mg·h/L, half-life 4.05 h. Convergence study yielded empirical orders 1.04 for Euler and 4.22 for RK4, matching theory. Multiple dosing every 8 h showed accumulation to periodic steady state with ratio 1.34. Nonlinear least-squares fitting of one-compartment model to simulated two-compartment data gave R²=0.910, quantifying approximation error. Normalized sensitivity analysis identified dose and bioavailability as unit-elastic for Cmax and AUC, clearance dominant for AUC (sensitivity -0.923). Optimization derived maintenance dose 611.8 mg q8h to sustain average steady-state 10 mg/L within window 4–18 mg/L, giving steady-state peak 13.94 and trough 5.45 mg/L. Renal impairment scenario showed this regimen exceeds toxicity under any impairment degree, with severe impairment (20% normal CL) producing peak 50.12 mg/L, nearly 3× toxic threshold. The study demonstrates that rigorous, validated pharmacokinetic modeling is essential for individualized dosing, especially with impaired clearance, and recommends dose adjustment linked to quantitative clearance estimates.
Chapter One Preview
Background to the Study
Pharmacokinetics models the body as compartments. The simplest, one-compartment open model, assumes instant mixing in blood and tissues, with first-order input from gut and first-order elimination. Bateman (1910) derived the analytical solution originally for radioactive decay chains, now central to pharmacokinetics. It produces a characteristic Bateman function: C(t) = (F·D·ka / V(ka-ke)) (e^{-ke t} - e^{-ka t}). For drugs distributing unevenly between well-perfused organs and poorly perfused fat/muscle, a two-compartment model adds a peripheral compartment linked by intercompartmental rate constants. These models explain why many drugs show biexponential decline.
Repeated dosing leads to accumulation via superposition principle. At steady state, concentration oscillates between peak and trough, with average concentration Css,avg = (F·D)/(CL·τ). The accumulation ratio R = 1/(1-e^{-ke τ}) depends only on elimination rate and interval. Renal impairment reduces clearance, prolongs half-life, and increases accumulation nonlinearly—clinically critical because prescribing without quantitative adjustment causes preventable adverse events. The FDA guidance on pharmacokinetics in renal impairment and NIH pharmacokinetics resources emphasize dose individualization. For related applied mathematics work, see mathematical modeling project materials
Statement of the Problem
Designing a regimen that keeps concentration within therapeutic window requires quantitative analysis; intuition alone underestimates nonlinear accumulation under reduced clearance. Introductory mathematics treatments often present single-dose Bateman solution without multiple-dose steady-state, numerical validation, two-compartment comparison, or sensitivity ranking, limiting decision value for dose adjustment in renal impairment. This study addresses gaps by providing fully specified, validated model, extending to multiple dosing and two-compartment fitting, conducting formal sensitivity and convergence analysis, and stress-testing regimen under renal impairment: how to design a regimen safe under normal clearance and quantify toxicity risk under impaired clearance?
Aim and Objectives
Aim: Develop, analyse, numerically validate compartmental pharmacokinetic model and apply to dosing design and renal impairment assessment.
Objectives:
1. Formulate one-compartment model with first-order absorption/elimination and derive Bateman solution.
2. Solve numerically via RK4 and validate against analytical and LSODA solver.
3. Compute Cmax, Tmax, AUC, half-life.
4. Extend to repeated dosing, characterize steady-state peak, trough, average, accumulation ratio.
5. Formulate two-compartment model and quantify error when approximated by one-compartment via nonlinear least squares (R²).
6. Conduct normalized sensitivity of Cmax and AUC to dose, bioavailability, ka, V, CL.
7. Compare Euler vs RK4 convergence.
8. Derive optimized maintenance and loading doses for therapeutic window 4-18 mg/L.
9. Simulate renal impairment effects on accumulation and toxicity risk.
Research Questions
1. What is analytical solution and how accurately does RK4 reproduce it?
2. What are Cmax, Tmax, AUC, half-life under baseline parameters?
3. How does concentration evolve under repeated dosing and what is accumulation ratio?
4. How well does one-compartment approximate two-compartment data?
5. Which parameters most influence Cmax and AUC?
6. What maintenance/loading doses sustain window and how robust to renal impairment?
Significance of the Study
For clinicians, provides reproducible framework for checking regimen safety under normal and impaired clearance, supporting individualized dosing. For mathematics community, demonstrates complete workflow: analytical derivation, numerical validation, superposition, nonlinear fitting, sensitivity, optimization. For students, illustrates ODE theory, numerical analysis, and regression in clinically relevant problem. For Nigerian public health, contributes to quantitative dose individualization in growing renal impairment population. See pharmacy and pharmacology project topics
Scope of the Study
Restricted to linear first-order compartmental models. Primary model: one-compartment open with first-order absorption/elimination for oral drugs with single-exponential distribution; two-compartment extension for comparison. Parameters representative of moderately hydrophilic renally cleared drug, not drug-specific primary data. Simulation: single-dose 24h horizon, multiple-dose 10 doses q8h to reach steady state. Renal impairment as proportional CL reductions representing mild/moderate/severe stages. Does not address nonlinear saturable kinetics, drug interactions, protein binding, or pharmacodynamics beyond fixed window.
Limitations
Parameters illustrative not drug-specific. Assumes linear dose-independent kinetics; many drugs show saturable kinetics. Inter-individual variability from genetics, age, body composition not explicitly modeled beyond renal scenarios. Two-compartment comparison uses simulated data. Fixed step RK4; adaptive/stiff solvers not explored for widely separated rate constants.
Operational Definition of Terms
Pharmacokinetics: Quantitative study of time course of absorption, distribution, metabolism, excretion.
Compartmental model: Body represented as well-mixed compartments linked by first-order processes.
Bioavailability (F): Fraction of dose reaching systemic circulation unchanged.
Clearance (CL): Theoretical volume cleared of drug per unit time.
Volume of distribution (V): Apparent volume relating total amount to plasma concentration.
Half-life (t1/2): Time for concentration to decline by half under first-order elimination.
Therapeutic window: Range between minimum effective and maximum safe concentration.
Accumulation ratio: Ratio of steady-state peak to single-dose peak under repeated dosing.
Sensitivity index: Normalized proportional change in output per proportional change in parameter.
FDA pharmacokinetics in patients with impaired renal function | NCBI StatPearls pharmacokinetics review | Bateman function derivation reference
Conclusion
Analytical Bateman solution validated numerically (RK4 error 5.45e-7 mg/L) predicts under baseline Cmax 8.09 mg/L at 1.9 h, AUC 65.38 mg·h/L, t1/2 4.05 h. Multiple dosing q8h accumulates with ratio 1.34; one-compartment approximates two-compartment with R² 0.910. Sensitivity shows dose and bioavailability unit-elastic, clearance dominates AUC. Optimized regimen 611.8 mg q8h sustains average 10 mg/L within 4-18 mg/L window (peak 13.94, trough 5.45 mg/L) but becomes toxic under any renal impairment, reaching 50.12 mg/L in severe impairment (20% CL). This underscores that dose adjustment must be linked to quantitative clearance estimates, not uniform reductions. For modeling templates, see our mathematical sciences project collection
FAQs
1. What is the Bateman function?
Analytical solution for one-compartment oral absorption: C(t) = (F·D·ka / V(ka-ke))(e^{-ke t} - e^{-ka t}), describing rise-and-fall plasma profile.
2. What were the single-dose predictions?
Under baseline 500 mg dose: Cmax 8.09 mg/L at 1.9 h, AUC 65.38 mg·h/L, half-life 4.05 h.
3. How accurate was RK4 numerical solution?
RK4 matched analytical within 5.45×10⁻⁷ mg/L and LSODA solver within 1.86×10⁻⁵ mg/L, confirming accuracy.
4. What is accumulation ratio?
Ratio of steady-state peak to single-dose peak, 1.34 under q8h regimen, indicating moderate accumulation.
5. How well does one-compartment approximate two-compartment?
Nonlinear least-squares fitting gave R²=0.910, showing reasonable approximation but measurable error from ignoring peripheral distribution.
6. Which parameters most affect drug exposure?
Dose and bioavailability have unit elasticity (1.0) for Cmax and AUC; clearance dominates AUC with sensitivity -0.923.
7. What dosing regimen was optimized?
611.8 mg every 8 hours to maintain average 10 mg/L within 4-18 mg/L window, giving steady-state peak 13.94 and trough 5.45 mg/L.
8. What happens in renal impairment?
Clearance reduction causes nonlinear accumulation. Regimen safe in normal function exceeds toxicity in all impairment levels, reaching 50.12 mg/L peak in severe impairment.
9. Why compare Euler vs RK4?
To demonstrate convergence: empirical order 1.04 for Euler vs 4.22 for RK4, matching theoretical 1 and 4, justifying RK4 for pharmacokinetic ODEs.
10. What are limitations of linear compartmental models?
Assume first-order kinetics, ignore saturable metabolism, protein binding, interactions, and inter-individual variability beyond clearance changes.
Purchase to unlock the full material.